Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

Abstract Background We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019. Methods CoronaVac-immunized adults (18–72 years) received a homologous or heterologous full or half dose SCB-2019 boost...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of infectious diseases 2023-11, Vol.228 (9), p.1253-1262
Hauptverfasser:	Roa, Camilo C, de Los Reyes, Mari Rose A, Plennevaux, Eric, Smolenov, Igor, Hu, Branda, Gao, Faith, Ilagan, Hannalyn, Ambrosino, Donna, Siber, George, Clemens, Ralf
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Clinical trials COVID-19 vaccines Immunogenicity Major Severe acute respiratory syndrome coronavirus 2 Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!